Qiaojun Fang

Qiaojun Fang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
JYJinlei Yang
Jinlei Yang
BTBin Tu
Bin Tu
GZGuangjie Zhang
Guangjie Zhang
PLPengchao Liu
Pengchao Liu
KHKui Hu
Kui Hu
ZTZhiyong Tang
Zhiyong Tang

5 May 2016 in Scientific Reports
Verified
Journal Article
Open access
HHHe Huang
He Huang
WLWenjia Lai
Wenjia Lai
MCMenghua Cui
Menghua Cui
LLLing Liang
Ling Liang
YLYuchen Lin
Yuchen Lin
LXLiming Xie
Liming Xie
Silver nanoparticles (AgNPs) have tremendous potentials in medical devices due to their excellent antimicrobial properties. Blood compatibility should be investigated for AgNPs due to the potential blood contact. However, so far, most studies are not systematic and have not provided insights into the mechanisms for blood compatibility of AgNPs. In this study, we have investigated the blood biological effects, including hemolysis, lymphocyte proliferation, platelet aggregation, coagulation and complement activation, of 20 nm AgNPs with two different surface coatings (polyvinyl pyrrolidone and citrate). Our results have revealed AgNPs could elicit hemolysis and severely impact the proliferation and viability of lymphocytes at all investigated concentrations (10, 20, 40 μg/mL). Nevertheless, AgNPs didn’t show any effect on platelet aggregation, coagulation process, or complement activation at up to ~40 μg/mL. Proteomic analysis on AgNPs plasma proteins corona has revealed that acidic and small molecular weight blood plasma proteins were preferentially adsorbed onto AgNPs, and these include some important proteins relevant to hemostasis, coagulation, platelet, complement activation and immune responses. The predicted biological effects of AgNPs by proteomic analysis are mostly consistent with our experimental data since there were few C3 components on AgNPs and more negative than positive factors involving platelet aggregation and thrombosis.

16 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MZMinzhi Zhao
Minzhi Zhao
CLChunni Lei
Chunni Lei
YYYadong Yang
Yadong Yang
XBXiangli Bu
Xiangli Bu
HMHuailei Ma
Huailei Ma
QFQiaojun Fang
Qiaojun Fang
P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance. Abraxane, a nanoparticle (NP) formulation of PTX, has multiple clinical advantages over the single molecule form. However, it is still unclear whether Abraxane overcomes the common small molecule drug resistance problem mediated by P-gp. Here we were able to establish an Abraxane-resistant cell line from the lung adenocarcinoma cell line A549. We compared the transcriptome of A549/Abr resistant cell line to that of its parental cell line using RNA-Seq technology. Several pathways were found to be up or down regulated. Specifically, the most significantly up-regulated gene was ABCB1, which translates into P-glycoprotein. We verified the overexpression of P-glycoprotein and confirmed its function by reversing the drug resistance with P-gp inhibitor Verapamil. The results suggest that efflux pathway plays an important role in the Abraxane-resistant cell line we established. However, the relevance of this P-gp mediated Abraxane resistance in tumors of lung cancer patients remains unknown.

27 December 2016 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
QXQi Xin
Qi Xin
QLQian Liu
Qian Liu
LGLingling Geng
Lingling Geng
QFQiaojun Fang
Qiaojun Fang
JGJian Ru Gong
Jian Ru Gong

1 April 2017 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
WLWenjia Lai
Wenjia Lai
QWQingsong Wang
Qingsong Wang
LLLumeng Li
Lumeng Li
ZHZhiyuan Hu
Zhiyuan Hu
JCJiankui Chen
Jiankui Chen
QFQiaojun Fang
Qiaojun Fang

1 January 2017 in Biomaterials
Verified
Journal Article
Closed access
ZXZhichu Xiang
Zhichu Xiang
XYXiaoliang Yang
Xiaoliang Yang
JXJunjie Xu
Junjie Xu
WLWenjia Lai
Wenjia Lai
Zihua WangZihua Wang
Zihua Wang
QFQiaojun Fang
Qiaojun Fang